Sequana Medical Investor Presentation November 2021

Sequana Medical presents innovations in treating diuretic-resistant fluid overload across liver disease, malignant ascites, and heart failure. The company discusses the alfapump® system, currently under clinical investigation in the POSEIDON Study, and DSR® therapy in development. The presentation includes regulatory status, risk factors, and forward-looking statements regarding the company's therapeutic solutions.